Clinical outcome of Pulsatile flow

Determination and comparison of the effect of 30 and 70 pulses in pulsatile cardiopulmonary bypass on clinical outcome of patients undergoing Coronary Artery Bypass Graft (CABG) surgery

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200602047642N1

Enrollment

Registered

2020-09-07

Start date

2020-06-23

Completion date

Unknown

Last updated

2020-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerotic heart disease. Atherosclerotic heart disease of native coronary artery

Interventions

Intervention 1: First intervention group: In the heart and lung pump machine, the pulse flow settings are as follows: Pulse number: 30, base flute: 30%, pulse width: 40%. After the pump starts and imm

Eligibility

Sex/Gender

All

Age

40 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patient satisfaction to enter the study Patients in the age range of 40-65 years Elective patients are candidates for Coronary Artery Bypass Graft surgery Patients with ejection fraction above 30%

Exclusion criteria

Exclusion criteria: Having a history of heart surgery Having another processor with Coronary Artery Bypass Graft Liver failure as ALT> 40 units / l AST> 40 units / l Preoperative pulmonary function test in the form of FEV1 <65% Having a creatinine level above 2 mg/dl Having a hemoglobin level of less than 10 mg/dl

Design outcomes

Primary

Measure	Time frame
Liver enzymes. Timepoint: Before, 24 and 48 hours after the operation. Method of measurement: Lab kits.;Renal enzymes. Timepoint: Before, 24 and 48 hours after the operation. Method of measurement: Lab kits.;Blood lactate. Timepoint: Before, 24 and 48 hours after the operation. Method of measurement: Lab kits.;Urine. Timepoint: Before the pump, during the pump, 12 and 24 hours after the operation. Method of measurement: Urine bag.;Bleeding. Timepoint: 12 and 24 hours after the operation. Method of measurement: Chest tube.;Inotropic consumption. Timepoint: 12 and 24 hours after the operation. Method of measurement: Yes/No.;Long stay at the intensive care unit. Timepoint: In the intensive care unit. Method of measurement: Hours recorded in the patient's file.;The duration of the intubation. Timepoint: In the intensive care unit. Method of measurement: Hours recorded in the file.	—

Measure

Time frame

Liver enzymes. Timepoint: Before, 24 and 48 hours after the operation. Method of measurement: Lab kits.;Renal enzymes. Timepoint: Before, 24 and 48 hours after the operation. Method of measurement: Lab kits.;Blood lactate. Timepoint: Before, 24 and 48 hours after the operation. Method of measurement: Lab kits.;Urine. Timepoint: Before the pump, during the pump, 12 and 24 hours after the operation. Method of measurement: Urine bag.;Bleeding. Timepoint: 12 and 24 hours after the operation. Method of measurement: Chest tube.;Inotropic consumption. Timepoint: 12 and 24 hours after the operation. Method of measurement: Yes/No.;Long stay at the intensive care unit. Timepoint: In the intensive care unit. Method of measurement: Hours recorded in the patient's file.;The duration of the intubation. Timepoint: In the intensive care unit. Method of measurement: Hours recorded in the file.

—

Secondary

Measure	Time frame
Consumption of blood and blood products. Timepoint: In the operating room and Intensive care unit. Method of measurement: Each unit of product consumed.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNeda Habibi

Rajaei Cardiovascular Hospital, Tehran

neda.nahi@yahoo.com+98 21 23921

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026